Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.
Hicks CB, DeJesus E, Sloan LM, Sension MG, Wohl DA, Liao Q, Ross LL, Pakes GE, Pappa KA, Lancaster CT; COL100758 Study Team. Hicks CB, et al. Among authors: pakes ge. AIDS Res Hum Retroviruses. 2009 Apr;25(4):395-403. doi: 10.1089/aid.2008.0231. AIDS Res Hum Retroviruses. 2009. PMID: 19320570 Clinical Trial.
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
Ross LL, Weinberg WG, DeJesus E, Fischl MA, Horton JH, Pappa KA, Lancaster CT, Pakes GE, Smith KY. Ross LL, et al. Among authors: pakes ge. AIDS Res Hum Retroviruses. 2010 Apr;26(4):407-17. doi: 10.1089/aid.2009.0189. AIDS Res Hum Retroviruses. 2010. PMID: 20380480 Free PMC article. Clinical Trial.
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.
Young B, Squires KE, Ross LL, Santiago L, Sloan LM, Zhao HH, Wine BC, Pakes GE, Margolis DA, Shaefer MS; Aries EPZ108859 Study Team. Young B, et al. Among authors: pakes ge. AIDS Res Hum Retroviruses. 2013 Feb;29(2):350-8. doi: 10.1089/aid.2012.0278. Epub 2012 Dec 5. AIDS Res Hum Retroviruses. 2013. PMID: 23039030 Free PMC article. Clinical Trial.
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Luber AD, Condoluci DV, Slowinski PD, Andrews M, Olson K, Peloquin CA, Pappa KA, Pakes GE; COL104422 Study Team. Luber AD, et al. Among authors: pakes ge. HIV Med. 2010 Mar;11(3):193-9. doi: 10.1111/j.1468-1293.2009.00765.x. Epub 2009 Oct 23. HIV Med. 2010. PMID: 19863619 Free article. Clinical Trial.
Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy.
Eron JJ Jr, Park JG, Haubrich R, Aweeka F, Bastow B, Pakes GE, Yu S, Wu H, Richman DD; ACTG5126 Study Team. Eron JJ Jr, et al. Among authors: pakes ge. Antimicrob Agents Chemother. 2009 Jun;53(6):2335-41. doi: 10.1128/AAC.01387-08. Epub 2009 Mar 23. Antimicrob Agents Chemother. 2009. PMID: 19307363 Free PMC article. Clinical Trial.
Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.
Collier AC, Tierney C, Downey GF, Eshleman SH, Kashuba A, Klingman K, Vergis EN, Pakes GE, Rooney JF, Rinehart A, Mellors JW; AIDS Clinical Trials Group Protocol A5143 Team. Collier AC, et al. Among authors: pakes ge. HIV Clin Trials. 2008 Mar-Apr;9(2):91-102. doi: 10.1310/hct0902-91. HIV Clin Trials. 2008. PMID: 18474494 Clinical Trial.
63 results